Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Reneo Pharmaceuticals Inc | RPHM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.675 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.675 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.9801 - 10.98 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.675 | USD |
Reneo Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 55.63M | 33.31M | - | 0 | -77.39M | -2.32 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Reneo Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RPHM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.64 | 1.92 | 1.64 | 1.74 | 153,688 | 0.035 | 2.13% |
| 1 Month | 1.68 | 1.92 | 1.63 | 1.71 | 99,651 | -0.005 | -0.30% |
| 3 Months | 1.63 | 1.92 | 1.55 | 1.65 | 190,416 | 0.045 | 2.76% |
| 6 Months | 7.85 | 8.29 | 0.9801 | 2.08 | 629,227 | -6.18 | -78.66% |
| 1 Year | 10.50 | 10.98 | 0.9801 | 3.18 | 394,535 | -8.83 | -84.05% |
| 3 Years | 13.03 | 14.95 | 0.9801 | 3.83 | 170,454 | -11.36 | -87.15% |
| 5 Years | 15.30 | 16.83 | 0.9801 | 3.97 | 170,531 | -13.63 | -89.05% |
Reneo Pharmaceuticals Description
| Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. |
